← SynDRA
GW786460X
SynDRA canonical compound SYN0005635 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | TGFBR1 |
|---|
| Mechanism of action | TGF beta receptor inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- TGF beta receptor inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- YES1
- ABL1
- PI4KB
- PAK3
- PAK5
- PAK6
- PASK
- PDGFRA
- PDGFRB
- PDK1
- PDPK1
- PHKG1
- PHKG2
- PIK3CA
- PAK1
- PIK3CD
- PIM1
- PIM2
- PIM3
- PLK1
- PRKAA1
- PRKAA2
- PRKACA
- PRKCA
- PRKCB
- PAK2
- NUAK1
- PRKCH
- NTRK3
- MAPKAPK3
- MAPKAPK5
- MARK1
- MARK2
- MARK3
- MARK4
- MELK
- MERTK
- MET
- MINK1
- MKNK1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- repsox
- RepSox
- ALK5 Inhibitor II
- 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine
- ALK5 Inhibitor
- SJN-2511
- RepSox (GMP)
- E-616452
- 2-[3-(6-Methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1,5-naphthyridine
- 2-[5-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]-1,5-naphthyridine
- RepsoxALK5 Inhibitor II
- CHEMBL185238
- C17H13N5
- 1,5-Naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-
- 2-(3-(6-Methylpyridine-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine
- 2-(3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl)-1,5-naphthyridine
- 2-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]-1,5-naphthyridine
- 1vjy
- Alk 5 Inhibitor II
- MLS006011123
- SCHEMBL144632
- RepSox (ALK5 Inhibitor II)
- SCHEMBL16969100
- ALK5 Inhibitor II hydrochloride
- RepSox, >=98% (HPLC)
- DTXSID80332295
- CHEBI:190969
- HMS2043P13
- HMS3261N03
- HMS3653M19
- AMY20099
- BCP04103
- EX-A2879
- Tox21_500541
- BDBM50151347
- HB3301
- HY-13012G
- MFCD09037561
- NSC756354
Look up GW786460X in the interactive SynDRA portal →